ANNUAL report 2011

EMERvEL
The international launch of the emervel
hyaluronic acid-based dermal filler range,
in January 2011, strengthened Galderma’s
position in the aesthetic procedures segment.
pany focused on its priorities: innovation,
med ical training and the consolidation of its
presence in the New Markets. Galderma continued
to expand in China, India and South-
East Asia, taking advantage of the structures
established by Q-Med, which has already a
notable presence in the region.
+8.4%
sALes growth (1)
Closer to the major markets
To keep pace with growing demand and
move as close as possible to its major markets,
Galderma intensified its industrial investment
programme in 2011. This led to more efficient
facilities, with an increased production
capacity of +40% and reduced costs, after an
extension of two main production platforms,
in France and Canada. Furthermore,
Galderma has increased its production
capacities in Brazil and now has a fourth factory
in Sweden.
(1) Like-for-like.
4
derMAtoLogy
r&d sites
a MOsaIC OF
russian
sUCCess
With cities such as Moscow, Saint Petersburg and Novosibirsk, the
Russian market offers Galderma a host of opportunities, which the
company began to seize several years ago. As patients’ expectations
in this country are extremely varied, it would be difficult to apply
a single strategy. Each region has specific needs and expectations,
which means the response must be specially adapted in each case.
The treatment of skin diseases and aesthetic medicine is growing
in importance in Russia. Over-the-counter sales in pharmacies,
the most dynamic segment for Galderma in this country, offer
a unique opportunity for direct contact with patients. The huge
success of Loceryl, for the treatment of fungal nail infections, is
a symbol of this winning strategy, underpinned by TV and online
advertising campaigns. Meanwhile, aesthetic and corrective
dermatology is booming, particularly in major cities. Through its
Q-Med division, Galderma offers a portfolio of products and services
for customised treatment to meet each patient’s expectations.
In the background, there is always a common denominator: the
training of healthcare professionals, which is the key to success.
With +47% growth (1) in 2011, Galderma performed very well
in Russia. The growth potential, like the country itself, is vast.
Now that Galderma boasts a major presence in eight Russian
cities, there is a dual ambition: to capitalise on Galderma’s
reputation to conquer new regions, and to become the
privileged partner of dermatology healthcare professionals.
67